BridgeBio Pharma, Inc. (BBIO)
Automate Your Wheel Strategy on BBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including BBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BBIO
- Rev/Share 0.6701
- Book/Share -8.618
- PB -3.8721
- Debt/Equity -0.0062
- CurrentRatio 4.5703
- ROIC -0.9611
- MktCap 6336328970.0
- FreeCF/Share -2.6708
- PFCF -12.477
- PE -9.4992
- Debt/Assets 0.0115
- DivYield 0
- ROE 0.4921
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BBIO | Redburn Atlantic | -- | Buy | -- | $50 | March 31, 2025 |
| Initiation | BBIO | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Initiation | BBIO | Oppenheimer | -- | Perform | -- | -- | Oct. 3, 2024 |
News
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes
Read More
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), …
Read More
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT.
Read More
BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Chinmay Shukla – Vice President-Strategic Finance Neil Kumar – Chief Executive Officer Matt Outten – Chief Commercial Officer Tom Trimarchi – President and Chief Financial Officer Ananth Sridhar – Chief Operating Officer-BridgeBio Cardiorenal Conference Call Participants Salim Syed – Mizuho Tyler Van Buren – TD Cowen Mani Foroohar – Leerink Partners Cory Kasimov – Evercore Greg Harrison – Scotiabank Paul Choi – Goldman Sachs Anupam Rama – JPMorgan Eliana Merle – UBS Jason Zemansky – Bank of America Operator Good afternoon. I …
Read More
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date
Read More
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO)
Published: April 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 23, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating BridgeBio Pharma, Inc. (NASDAQ: BBIO) on behalf of the company's shareholders. The investigation seeks to determine whether BridgeBio Pharma's directors breached their fiduciary duties in connection with recent corporate actions.
Read More
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025.
Read More
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Published: March 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time to all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH) in both variant (ATTRv) and wild-type (ATTRwt) transthyretin amyloid cardiomyopathy (ATTR-CM) patients from a pre-specified subgroup analysis of ATTRibute-CM, its Phase 3 trial of acoramidis in ATTR-CM. These data were presented at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo in a poster presentation …
Read More
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% …
Read More
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.
Read More
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of notes. The sale of the notes is expected to close on February …
Read More
BridgeBio: Strong Start For Attruby
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive
Attruby is off to a strong start in the United States, with more than 1,000 unique prescriptions in less than three months since FDA approval. I now see more patients on Attruby by year-end than I anticipated at launch, although the pace could moderate in Q2 following the approval and launch of Alnylam's Amvuttra. The company's pipeline is advancing as well, with three pivotal trials set to report data within the next 12 months.
Read More
BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Negative
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.96 per share a year ago.
Read More
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of …
Read More
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on February 20, 2025. As part of the announcement, the Company will also share updates on Attruby's commercialization progress and its late-stage clinical pipeline.
Read More
About BridgeBio Pharma, Inc. (BBIO)
- IPO Date 2019-06-27
- Website https://www.bridgebio.com
- Industry Biotechnology
- CEO Dr. Neil Kumar Ph.D.
- Employees 725